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ABSTRACT: 
Background: 
The likelihood of developing Diabetes Mellitus increases with the upper limit of 
body mass index. Genetic, lifestyle and environmental factors combined together 
promotes obesity. Diabetes mellitus is associated with alterations in carbohydrate, protein 
and fat metabolism due to defective insulin secretion or action or both. Leptin the product 
of ob gene is secreted by adipocytes and also by placenta, bone marrow, muscle, etc. It 
has a major role in maintaining body weight and in energy metabolism. The 
hypothalamus is the predominant site of action of Leptin. Receptors for Leptin is present 
in various sites like brain and peripheral tissues like pancreas, liver, lungs, adipose 
tissues, T-lymphocytes and epithelial cells. This gives the evidence for the role of Leptin 
in carbohydrate metabolism, reproduction and many other functions. Leptin exhibits its 
insulin lowering action through the receptors present in beta cells of pancreas. 
Objectives: 
1. To form four groups namely obese type 2 diabetic (n=40), thin type-2 diabetes 
mellitus (n=40), obese non-diabetic (n=40) and thin non-diabetic (n=40) according 
to inclusion and exclusion criteria. 
2. To collect relevant data and sample for Leptin estimation.  
3. To estimate Leptin using ELISA method. 
4. To compare the data between 4 groups. 
5. To analyze the correlation between the quantitative parameters. 
Study design: 
 Case Control study. 
Study population: 
After obtaining institutional human ethics committee approval,40 subjects in each 
of the four groups namely thin diabetic, obese diabetic, thin non-diabetic and obese non-
diabetic populations (n=160) were selected. Leptin and other parameters were measured. 
Results:  
It was found that there was no significant difference in Leptin levels in both obese 
diabetic and obese control groups. Leptin level was confined to the lower side in thin 
groups. There was a significant positive correlation between Leptin and body mass index. 
Female subjects have got increased Leptin value than male subjects. 
 Conclusion: 
1. Leptin is not elevated in thin diabetic when compared with thin non-diabetic. The 
development of type 2 diabetes mellitus in thin individuals may not be related to 
Leptin level. 
2. Obesity and Female sex are associated with increased Leptin level and not with 
type 2 diabetes mellitus. 
3. BMI and Leptin have a linear positive correlation. 
Key words: Leptin, diabetes mellitus, body mass index. 
 
 
INTRODUCTION 
Diabetes mellitus (DM) is a metabolic disorder of several etiologies. It is 
characterized by chronic hyperglycemia associated with alterations in the metabolism of 
carbohydrate, fat and protein. It results from defective secretion of insulin, action of 
insulin or both
1
.Two major forms of diabetes were recognized: type 1 and type 2. Lack of 
or severe reduction in insulin secretion due to autoimmune or viral destruction of β cells 
is responsible for type 1 diabetes, which accounts for 5-10% of diabetic patients. The 
more prevalent form type 2 diabetes constitutes for more than 90% of diabetic patients. 
Type 2 diabetes is characterized by insulin resistance, as a result of which the cells do not 
use insulin appropriately. As a consequence of resistance to insulin, the need for insulin 
rises and the pancreas progressively loses its ability to produce it. Type 2 diabetes and its 
complications urge an immense burden both on individuals with diabetes and on 
healthcare systems
2
. 
 
 Studies in the past shows that central obesity is strongly associated with type 2 
DM in Indian population. Overweight and increase in age are the two main factors 
contributing to the progression of type 2 DM. Currently body weight is influenced by 
factors such as poor diet and drugs like sulphonylurea, insulin,etc
3,4
. 
 
Though we consider obesity and older age as risk factors of type 2 diabetes, recent 
studies shows that type 2 diabetes is much common in younger aged patients. In a US 
 
 
based study 33% increase in the incidence and prevalence seen during the past decade is 
due to type 2 diabetes occurring in children and young adults. In 1992, it was rare for 
most pediatric centers to have patients with type 2 diabetes. By 1994, type 2 diabetes 
accounted for up to 16% of new cases of pediatric diabetes in urban areas, and by 1999, it 
accounted for 8–45% of new cases depending on geographic location5.   
The association between obesity and type 2 diabetes also has to be reexamined. 
Not all type 2 diabetics are obese and not all obese are type 2 diabetic. In an Indian study 
on the prevalence of obesity in type 2 diabetes, it was found that only 20% are obese 
(BMI above 30), 26.7% are overweight (BMI 26-30), 43.3% normal weight (BMI 20-25) 
and interestingly 10% are underweight (BMI below 20).  Many studies focus rather on 
central obesity based on waist hip ratio instead of obesity based on BMI, mainly due to 
lack of convincing association. In the same, Shilpi Sharma and Shashi Jain study, 85% of 
Female type 2 diabetic had abdominal obesity. Still, only 40% of males with type 2 
diabetes had abdominal obesity. So, type 2 diabetes may represent a heterogeneous group 
and may not be equated to obesity
6
.  
 
       Leptin, the product of ob gene, is a peptide that is strongly correlated with 
adiposity. Leptin, a protein hormone made of 167 aminoacids is produced by adipocytes. 
It is considered to have a role in regulation of body weight and energy metabolism
7
. 
Leptin along with other adipokines influences insulin sensitivity and is established to be 
responsible for the pathogenesis of obesity associated disorders
8
. Increased level of serum 
Leptin is considered as a component of metabolic syndrome
9
. It was suggested that 
 
 
resistance to Leptin in β-cells results in hyperinsulinemia due to the inhibitory effect of 
Leptin on insulin secretion. This may lead to the exhaustion of β-cells in the pancreas 
leading to the progression of Type 2 DM
10
. Previous studies showed a strong positive 
correlation of Leptin with body mass index (BMI) and body fat in non-obese and obese 
subjects with Type 2 diabetes mellitus
11
.  
 This study is an attempt to understand the thin built patients with type 2 diabetes 
mellitus. As obesity and type 2 diabetes are tightly linked, whether any of the lipokines 
got dysregulated in some thin individual leading to type 2 diabetes is the suspicion. Out 
of all lipokines, Leptin is very well associated with obesity. So, in this study we wanted 
to examine whether Leptin level is elevated in thin diabetic. That is, whether Leptin level 
has association with type 2 diabetes independent of obesity status, will be examined in 
this study. This question will be answered by studying the association between obesity, 
Leptin levels and type 2 diabetes.  
 
 
 
 
 
 
 
 
 
 
AIM & OBJECTIVES 
Aim: 
To compare the levels of serum Leptin in thin type-2 diabetes mellitus, thin non-diabetic, 
obese type-2 diabetes mellitus & obese non-diabetic. 
 
Objectives: 
1. To form four groups namely obese type 2 diabetic (n=40), thin type-2 diabetes 
mellitus (n=40), obese non-diabetic (n=40) and thin non-diabetic (n=40) according 
to inclusion and exclusion criteria. 
2. To collect relevant data and sample for Leptin estimation.  
3. To estimate Leptin using ELISA method. 
4. To compare the data between 4 groups. 
5. To analyze the correlation between the quantitative parameters. 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 Diabetes mellitus is the major non-communicable disease which is prevalent 
worldwide. It is a multifactorial metabolic disorder characterized by chronic 
hyperglycemia. It is associated with alterations in carbohydrate, protein and fat 
metabolism due to defective insulin secretion or action or both
12.
 
 
Epidemiology of diabetes mellitus: 
Worldwide occurence of diabetes mellitus in adult population (20-79 years old) is 
estimated to be around 8.3% with 382 million people suffering from diabetes .North 
America and the Caribbean region has got the highest prevalence of disease (11%) 
followed by the Middle East and North Africa (9.2%)
13 
. Type 2 DM accounts for 
approximately half of adolescent diabetes in the United States, and one-third of these 
cases were undiagnosed
14
.
 
It was estimated that nearly 1 million Indians die due to 
diabetes every year with the average age of onset being 42.5 years and it is expected that 
by 2030 incidence will increase possibly due to increased prevalence of obesity and lack 
of physical activities
15,16
. Prevalence of diabetes mellitus is higher in men less than 60 
years of age when compared to women at older ages
17
. Majority of people with diabetes 
are in 45 to 64 years of age in developing countries, whereas in developed countries most 
of them are greater than 64 years of age
18
.
 
The prevalence of Type 2 diabetes is high and 
it is 4-6 times elevated in urban parts of India than in rural sector
19
. At present, India 
stands next to China with 63 million population diagnosed with diabetes due to obesity
20
. 
 
 
Criteria for diagnosing diabetes mellitus
21
: 
 Glycated hemoglobin ≥ 6.5% or 
 Fasting Plasma Glucose (FPG) ≥ 126 mg/dL or 
 2-hour plasma Post prandial  glucose ≥ 200mg/dL during an Oral Glucose 
Tolerance Test or 
 Random plasma Glucose ≥ 200 mg/dL with signs and symptoms of 
hyperglycemia. 
 
Type 2 diabetes mellitus: 
The major prevalent type of diabetes is type 2. It affects greater than 90% of the 
population suffering from diabetes globally. There is a rapid increase in the number of 
diabetic patients and this fiery growth is noted in both rural and urban areas. It is 
characterized by excessive hepatic glucose production, variable degree of resistance to 
insulin action, decreased insulin secretion, and abnormalities in fat metabolism. 
 
Risk factors for type 2 diabetes mellitus
21
: 
Sedentary life, lack of physical activity, diet, lifestyle changes and related 
epidemiological conversion has been established as risk factors for type 2 DM. Other 
major risk factors are listed below. 
 Family history of diabetes mellitus 
 
 
 Overweight with Body Mass Index, BMI ≥ 25 kg/m2 
 Decreased physical activity 
 Ethnicity  
 Previously identified to have IFG/IGT 
 Blood pressure ≥ 140/90 mm of Hg 
 Triglycerides ≥ 250 mg/dL 
 High Density Lipoprotein (HDL) ≤ 35 mg/dL 
 Previous History of Gestational diabetes mellitus 
 Polycystic ovary syndrome. 
 
Pathogenesis of Type-2 DM:  
 Type-2 DM is found to result from a synergy between genetic and acquired 
etiologies. This adversely influences the function of beta cell and also on the insulin 
sensitivity of the tissues
22
. For several years it was notorious whether the derangements in 
beta cell function or resistance to the insulin action was the primary underlying causal 
element. The focus on insulin resistance being the key defect has been traced back to the 
classic studies of Himsworth and Kerr
23
. Insulin resistance was found to result from a 
blend of genetic as well as environmental factors. 
 
 
 
 
 
Insulin resistance:  
It is defined as the deprivation of insulin to exert its biological functions at 
effective circulating levels in normal subjects
24
. It is found in non-diabetic individuals 
who are obese and in patients with Type-2 DM. It is a distinctive sign of defective action 
of insulin. There is an extensive scientific continuum of resistive action of insulin varying 
from euglycemic status with a remarkable augmentation in insulin secretion by the 
pancreatic islet cells to hyperglycemia in spite of increased doses of exogenous insulin. 
Loss of beta-cell function: 
 The impairment of beta cell function is allied with the insulin resistance mediated 
increased beta-cell demand which is required for developing increased glucose values in 
fasting status. The foremost flaw is loss of secretion of insulin that is induced by glucose 
labelled as selective glucose insensitivity. Excess increase in blood glucose levels renders 
the beta cells insensitive to glucose. The extent of beta cell dysfunction is found to be 
associated with both glucose concentration and duration of hyperglycemia. The normal 
pulsatile secretion of insulin is also found to be disturbed. 
Diabetogenes:  
Genetic factors also pave way to the progression of diabetes. Genes that affect beta 
cell apoptosis, beta cell regeneration, sensing glucose levels, ion channels, energy 
transduction, microtubules or microfilaments, metabolism of glucose and other islet 
proteins mandatory for the synthesis, binding, progress and discharge of secretory 
granules
25
. Until recently, only a small number of polymorphisms have been identified as 
 
 
risk factors: One involves amino acid genetic variations in the peroxisome proliferator 
activated receptor gamma which is expressed in target tissues of insulin action and beta 
cells. Second involves the gene encoding a cysteine protease namely calpain-10, which 
modulates insulin release as well as insulin actions on skeletal muscle and adipose 
tissue
26
. Numerous genetic factors along with exogenous factors like environmental 
agents together contribute to the increased glycemic state of the individual. However, 
despite extensive work, the genes leading to Type-2 diabetes remains indefinite. 
Environment:  
Environmental factors ranging from dietary habits to level of physical activity are 
chief determinants in the development of Type-2 DM. Obesity is associated with insulin 
insensitivity and is the most significant predictive risk factor for development of Type-2 
DM. It is found to be mediated by a variety of factors released from adipose tissue such 
as leptin, adiponectin and many others which adversely affect functions of beta cell. An 
inverse relationship exists between the level of physical activity and the prevalence of 
Type-2 DM. Exercise is thought to produce an increased sensitivity to insulin in skeletal 
muscle and adipose tissue. 
Dyslipidemia in diabetes mellitus: 
Insulin resistance in the perception of glucose metabolism leads to impairment in 
the suppression of endogenous glucose production under basal and fasting conditions. It 
also leads to reduced peripheral uptake of glucose. Insulin suppresses the production of 
very low density lipoprotein (VLDL). Resistance to this action of insulin increases 
circulating serum triglycerides levels. Resistance to insulin action in the adipose tissue 
 
 
increases the discharge of non-esterified fatty acids (NEFA) both to the liver and skeletal 
muscle. This impairs the actions of insulin on glucose metabolism in these tissues. 
Evidence from previous studies suggested that insulin normally suppresses the production 
of VLDL, especially VLDL -1 apo-B particles from the liver
27
. This effect is brought 
about by decrease in availability of non-esterified fatty acids and also a direct effect of 
insulin on the liver cells where it inhibits the assembly and synthesis of VLDL particles
28
. 
In discrepancy to normal subjects, insulin fails to restrain VLDL apo- B production in 
those with Type-2 DM, though insulin profoundly lowers NEFA concentrations. 
Overproduction of VLDL and the defective insulin mediated inhibition of VLDL 
production are found to be one main causative reason for the increase triglyceride 
concentrations in subjects with insulin resistant Type-2 DM
29
. 
     Reduction in HDL levels in patients with insulin resistance accompanied by 
elevated triglycerides. Increased switching of triglycerides and cholesteryl esters, 
between high density lipoproteins and others that are rich in triglyceride, by cholesterol 
ester transfer protein (CETP) in conditions producing a hypertriglyceridemic state. 
Finally the HDL particles are enriched with triglycerides which make them susceptible to 
the action of hepatic lipase thereby clearing HDL from the systemic circulation at an 
increased pace. Further suboptimal activity of lipoprotein lipase (LPL) leads to fall in 
HDL cholesterol levels by diminishing the inter-exchange of HDL-3 to HDL-2 
particles
30
. 
  Prominent rise in the level of VLDL particles in diabetic patients elevates the 
transfer of cholesterol esters and triglycerides between VLDL and LDL, mediated by 
 
 
CETP. The increase in triglyceride level in LDL particles creates an environment 
susceptible for the action of hepatic lipase
31
. This enzyme hydrolyses triglycerides 
present in LDL thereby increasing their mass. The above said events are the reason for 
Type-2 DM individuals having small and dense LDL compared with individuals without 
diabetes
32
. The association between insulin resistance and cardiac disease
 
are due to the 
atherogenecity of smaller and denser LDL
33
. 
 
Glycated haemoglobin (HbA1c): 
It is a well-known indicator of glucose levels in blood over a prolonged phase of 
time. Biochemically, glycation is the attachment of a sugar moiety to amino groups of 
proteins which occurs spontaneously without the need for an enzyme.  Adult hemoglobin 
is composed of four polypeptide chains, two alpha and two beta chains. Glycated 
hemoglobin is formed by reaction of glucose with the amino terminal valine residue of 
any one of the β-chains of HbA to produce an unsteady Schiff base. This unstable Schiff 
base is reversible. This undergoes Amadori rearrangement to form a stable conjugate 
referred to as glycated haemoglobin. This reaction when it occurs between glucose and 
other proteins leads to the synthesis of advanced glycation end products (AGE) which 
contributes to the micro and macro vascular complications of DM. Adhesion of plasma 
proteins in the altered blood vessels contributes to accumulation of LDL and consequent 
atherosclerosis. The cut-off limit was set at a level of 6.5%.The American Diabetes 
Association acknowledged this decision. The traceability of the method should be to the 
Diabetes Control and Complications Trial reference assay
34
. 
 
 
 
 
Obesity: 
Obesity is defined as the condition of surplus mass of adipose tissue. Obesity is 
efficiently associated with morbidity and mortality. The body mass index (BMI) is 
commonly employed to measure obesity. This is calculated by the formula which uses 
height and weight. It is defined as the weight in kilograms divided by the square of the 
height in meters (kg/m
2  
).Other methods to quantify obesity are anthropometry (skin-fold 
thickness), densitometry (underwater weighing),Computed tomography (CT) or Magnetic 
Resonance Imaging (MRI), and electrical impedance
35
. 
 
World Health Organisation (WHO) has given the cut –off values for classifying 
persons based on body mass index. Under this they are classified as underweight, normal 
weight, over weight and obese persons. These values given for Body Mass Index are not 
dependent on age. The given values are same for both sexes. Due to variations in body 
proportions, body mass index will not correspond to the same degree of fat. The adverse 
effects of health are continuous with increasing BMI. The associations between body 
mass index and health risks are different in different populations. 
 
 
 
 
 
 
Table 1: BMI BASED CLASSIFICATION OF WEIGHT IN ADULTS
36,37
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification Body mass index(kg/m
2
) 
 Principal cut-off points Additional cut-off points 
Underweight- 
Thin 
<18.50 <18.50 
     Severe  <16.00 <16.00 
     Moderate 16.00 - 16.99 16.00 - 16.99 
     Mild  17.00 - 18.49 17.00 - 18.49 
Normal range 18.50 - 24.99 18.50 - 22.99 
23.00 - 24.99 
Overweight ≥25.00 ≥25.00 
     Pre-obese 25.00 - 29.99 25.00 - 27.49 
27.50 - 29.99 
Obese ≥30.00 ≥30.00 
    Class I  Obese 30.00 - 34.99 30.00 - 32.49 
32.50 - 34.99 
   Class II Obese 35.00 - 39.99 35.00 - 37.49 
37.50 - 39.99 
   Class III  Obese ≥40.00 ≥40.00 
 
 
 
The deposition of fat in varying anatomic locations also has its own effect on morbidity. 
Among the distribution, intra-abdominal and abdominal subcutaneous fat is given a 
distinct importance. The determination of abdominal fat is done by measuring waist-to-
hip ratio. If the ratio is more than 0.9 in women and more than 1 in men is abnormal. If 
an abnormal waist to hip ratio exists, then a person is more prone to develop many 
complications. The major complications are resistance to insulin, diabetes, increase in 
blood pressure, lipid profile and androgen secretion in women. Intra-abdominal and/or 
upper body fat is more strongly correlated to these complications than to overall 
adiposity. Due to excess fat storage, more free fatty acids are discharged into the portal 
circulation. This will have an adverse metabolic action on the liver. 
 
The Adipocyte and Adipose Tissue:  
The function of adipocytes as endocrine cell is to release various molecules. This 
includes Leptin which helps in maintaining equilibrium of energy, cytokines like tumor 
necrosis factor  and interleukin-6, complement factors likefactor D (adipsin), 
plasminogen activator inhibitor I which is a prothrombotic activator, and angiotensinogen 
involved in maintaining blood pressure. This is carried out in a synchronized manner. 
 
 
 
 
FACTORS SECRETED BY THE ADIPOCYTES: 
 
Source: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Jameson JL, Loscalzo 
J.Harrison‟s Principles of Internal Medicine, 17th edition: Chapter 74 Biology of Obesity. 
Page: 464. 
 
Etiology of Obesity
35
:   
Environmental factors: 
The body weight is inherited in the same manner as that of height. Both the genes 
and the environment plays an important role in becoming obese. Among the genes and 
environment, environment plays an important role in obesity. Another important factor in 
gaining obesity is that the genes will increase the propensity of obesity with respect to 
 
 
specific diets and nutrition. One more factor playing a key role in obesity is the cultural 
factors. This is related to the accessibility to the diets and also the composition of the diet. 
It is greatly influenced by the level of physical work. Obesity is greatly promoted by diets 
which are rich in high fats particularly which is combined with simple carbohydrates 
contrasting complex carbohydrates. 
 Genetic factors: 
  Obesity is also related to some genetic syndromes caused by mutations. One such 
is the mutation of ob gene. Mutations affecting Leptin and its receptor have been 
discovered in many families presenting with morbid, early onset obesity. This paves way 
for illustrating the biological association of Leptin in human beings. 
PHYSIOLOGICAL ROLE OF LEPTIN: 
 
 
 
 
 
Other gene mutations linked to obesity are: 
POMC Pro-opiomelanocortin, a precursor of several hormones and neuropeptides 
MC4R  Type 4 receptor for MSH 
PC-1 Prohormone convertase 1 
TrkB  TrkB, a neurotrophin receptor 
Syndromes linked with obesity are Cushing's Syndrome, Hypothyroidism, Insulinoma, 
Craniopharyngioma and Other Hypothalamic Disorders. 
Pathogenesis of Obesity
35
: 
Excessive intake of energy, diminished expenditure of energy, or both leads to the 
development of obesity. Measuring both the parameters is necessary for finding the cause 
of obesity. The body weight is maintained by the mechanisms involving adipose tissue 
and hypothalamus. This physiological action is maintained by a system which acts as a 
sensor in adipocytes that reveals the lipid stores and their receptor/ "adipostat" being 
present in the centres of hypothalamus. During  the fat in the body being used up, the 
adipostat signalling will be low, and the response shown by hypothalamus is by 
triggering hunger and declining the energy expenditure to save energy. Opposite effect 
occurs when the fat stores are in excess. The molecular basis for this physiological notion 
 
 
has been arrived at following the breakthrough finding of the ob and db genes and their 
respective products namely Leptin and its receptor.  
Leptin: 
Leptin is a 16 kilo Dalton protein hormone made up of 167 amino acids. It is 
derived from the Greek word „leptos‟ which means lean.  It is coded by ob gene present 
on chromosome 7 in humans. It plays a vital part in regulation of food ingestion, 
balancing energy and functions as a metabolic and neuroendocrine hormone. The 
foremost function of leptin is in regulating body weight.  
STRUCTURE OF LEPTIN 
                     
Source: Essan et al. A Review: Leptin Structure and Mechanism actions. BEPLS 
April 2014; Vol 3 (5):185 -192. 
 
 
 
 
Leptin is one of the most important hormone secreted by adipocytes into the 
bloodstream
38
. Two circulatory forms of Leptin have been found. One as the free form in 
plasma and other is associated with Leptin binding protein. The latter includes a type of 
Leptin receptor which is soluble. It is opted that, the major part of Leptin is found as a 
bound form in thin built individuals and in obese individuals as free form
39 
. 
 
Central actions: 
Leptin receptors were located in the choroid plexus and hypothalamus, a region 
regulating intake of food, appetite and weight. Lepti binds to its receptor and acts mainly 
to inhibit hunger
 
by the following mechanisms
40,41
: 
1. It opposes the effects of Neuropeptide Y, which is secreted by cells of gut and 
hypothalamus and serves to stimulate hunger.  
2. It has antagonistic action of Anandamide which also promotes hunger and it 
exhibits its action by binding to the same receptors as Tetrahydrocannabinol. 
3. It enhances the synthesis of alpha -melanocyte stimulating hormone which 
functions as a hunger suppressant. 
4. It acts on receptors in the Mediobasal hypothalamus and controls food ingestion 
and energy expenditure
42
. 
 
 
These mechanisms produce neuronal signals which make a person to consume less 
food and to metabolize more amounts of fuels
43
. 
Peripheral Actions: 
Leptin also exerts its effects on organs other than hypothalamus. These effects on 
peripheral targets are due to the distribution of Leptin receptors on various cell types. The 
various peripheral actions of leptin are: 
1. Regulation of energy expenditure. 
2. Harmonizing fetal and maternal metabolism. 
3. Role in puberty. 
4. Activation of immune cells and pancreatic beta islet cells. 
5. Interaction with other energy regulatory hormones like insulin
44
. 
Mechanism of action: 
The transduction of the Leptin signal is by the Janus kinase – signal transducers 
and activators of transcription pathway(JAK-STAT). The structure of Leptin receptor has 
a single transmembrane segment. This receptor has two monomers and when Leptin 
binds to the extracellular domain, it dimerizes. Janus kinase (JAK) acts on the 
intracellular domain by phosphorylating both the monomers on tyrosine residues. These 
 
 
residues which are phosphorylated becomes the site of docking by STAT sometimes 
called fat-STATS. These three proteins serve as signal transducers and activators of 
transcription. Janus kinase (JAK) phosphorylates tyrosine residues of the docked STATs. 
Now the dimerized STAT shifts to nucleus. After shifting, they attach to the target DNA 
sequences and the activation of the genes expression occurs. This includes the gene for 
POMC (pro-opiomelanocortin) by which α – melanocyte stimulating hormone is 
secreted. 
 
Leptin causes increased production of thermogenin, a product of UCP1 
(uncoupling protein 1) gene. This is a mitochondrial uncoupling protein produced in 
adipocytes whose effects are increased catabolism and thermogenesis. The mechanism by 
which Leptin stimulates the formation of thermogenin is by changing the transmission of 
impulses from  arcuate nucleus neurons to adipose tissue and others. In adipose tissue 
Leptin increases the secretion of norepinephrine and the action is exhibited through beta 
3 adrenergic receptors, which leads to the UCP1 gene transcription. This paves the way 
for the uncoupling of  transfer of electrons from oxidative phosphorylation. This utilizes 
fat and becomes thermogenic
45
 . 
  
 
 
 
 
 
 
 
 
 
 
Leptin signal transduction in the hypothalamus by JAK-STAT mechanism: 
 
            
 
 
Source: Dave Nelson and Mike Cox. Lehninger Principles of Biochemistry 5
th
 
edition.chapter 23: Hormonal Regulation and Integration of mammalian Meatbolism. 
Page no 933. 
  
 
Obesity and diabetes:  
Obesity and diabetes, altogether known as diabesity, is the evolving metabolic 
disease of developed and developing countries. The risk of developing type 2 diabetes 
mellitus increases with the upper normal limit of body mass index. Both men and women 
carry equal risk. Another important risk factor is the duration of obesity. EPIC Potsdam 
cohort study showed that an increase in BMI of one unit between the age group of 25 to 
40 years elevates the relative risk of  diabetes by 25%
46
. The chance of developing 
metabolic syndrome rises even with low degree of overweight, upper normal range of 
body mass index and the pattern of fat distribution. Obesity encompasses increased 
insulin secretion and decreased hepatic insulin clearance. As a result of obesity, diabetes 
will be developed by obese people who had a genetic failure of pancreas to compensate 
for insulin resistance
47
 
Developmental programming of obesity and diabetes: 
Maternal hyperglycemia and long time over nutrition during pregnancy 
predisposes the fetus to develop many adverse consequences. It includes 
 
 
hyperinsulinemia, hypercortisolemia and hyperleptinemia. As the hypothalamus is 
involved in energy homeostasis and metabolism, these consequences will result in 
malprogramming. This will lead to a increase in lifetime risk of developing diabetes. Due 
to these effects other adverse health effects may occur. Epigenetic processes like DNA 
methylation, histone modification and change in the microRNA pattern are all concerned 
with these mechanisms
48
. 
Environmental factors promoting obesity and diabetes: 
 Current worldwide epidemic of obesity and diabetes is caused by the vast 
alteration in the lifestyle and environmental factors. In the past 20-30 years a dramatic 
change has taken place in the eating habits, food choices and physical activity. Fast foods 
have taken the foremost role in promoting obesity and diabetes. The evidence for this 
comes from a study conducted by Rosenheck
49
.  Olsen et al have highlighted the usage of 
high consumption of calorically sweetened beverages
50
. The high energy density of 
modern foods is also implicated in undesirable health effects. 
 
                    The study conducted by Prentice et all gives an alarming fact that average 
energy density of fast foods are 65% higher than the healthy diets. They also add that 
these energy dense foods challenges human appetite control systems with conditions for 
which they are never developed
51
. The final and a strong determinant of developing 
obesity and diabetes is the socioeconomic status.  
 
 
 
 
 
 
 
 
 
 
 
Pathophysiological link involving obesity and type 2 diabetes: 
 
In obesity there is a surplus production of non-esterified fatty acids from 
adipocytes. Glucose consumption is competed and there is a blockade of glycolytic 
enzymes pyruvate dehydrogenase, phosphofructokinase and glucokinase. Due to this, 
blood glucose levels increase and glucose oxidation is declined. Glycerol is formed from 
the fatty acids which are produced in excess amount and utilizes for hepatic glucose 
production. This will enhance the imbalance of carbohydrate metabolism. In obese 
diabetic patients insulin resistance favours elevated intramyocellular lipid accumulation. 
Ceramide, diacylglycerol and coenzyme A accumulates in the muscle because of too 
much delivery of fatty acids. This leads to the impairment of insulin mediated serine-
threonine kinase cascade finally ensuing the serine-threonine phosphorylation of insulin 
receptor substrate 1 and 2 (IRS -1 &2). Thus, insulin signaling is destructed which ends 
up in insulin resistance
52
. When glucose levels rise due to raised fatty acids, impairment 
 
 
of insulin secretion is mediated through the increased expression levels of Uncoupling 
protein 2 (UCP-2) in beta cells of pancreas
53
.  
           
 
 
 
 
CELLULAR MECHANISMS FOR INFLAMMATION AND DEVELOPMENT OF 
INSULIN RESISTANCE: 
                  
 
 
Source: Shoelsen SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin 
Invest 2006; 116: 1793 – 801. 
Lipids stimulate the c-Jun N-terminal kinase (JNK) and IKK β – NF –kβ pathway which 
serves to mediate the inflammation in adipose tissue. In this pathway IRS-1 gets 
phosphorylated leading to insulin resistance. JNK activity is elevated in adipose tissue, 
liver and muscle
54
. It was recently highlighted that hypertropic fat cells leads to 
proinflammatory state relating with type 2 diabetes
55,56
. In a state of excess glucose, stress 
was created in endoplasmic reticulum interfering insulin signaling. This was with inositol 
requiring kinase-1α (IRE-1α) activating c-Jun N-terminal kinase pathway57. Pre-
adipocytes and adipocytes secrets many chemokines attracting monocytes and 
macrophages through stromal cell derived factor 1 (SDF-1). This process mediates 
inflammation ending up in metabolic and cardiovascular complications of obesity
58,59
. 
 
OBESITY AND INSULIN RESISTANCE: 
 
 
 
 
 
 
Source: de Luca C, Olefsky JM.Stressed out about obesity and insulin resistance. 
 Nat Med. 2006 Jan; 12(1):41-2 
 
Leptin and diabetes: 
The expression of Leptin can be harmonized by insulin. This is supported by many 
studies and the effect is exerted by insulin mainly by stimulating mRNA expression. 
These studies were conducted in isolated adipocytes
60-64
. Leptin levels are increased for a 
longer period when hyperinsulinemia was induced by clamp techniques
62,65-67
. Leptin 
receptors are also found on pancreatic beta cells which secrete insulin
68
. The insulin 
secretion is lowered by the action of Leptin mediated through these receptors. The way 
by which insulin secretion is synchronised is through phospholipase C (PLC)/ protein 
kinase C (PKC) mediated pathways.  The first phase of this pathway involves the 
lowering of intracellular calcium levels which is linked with the activation of ATP-
sensitive potassium channels
69,70
. The second phase in the pathway includes the inhibition 
of calcium dependent mediator, protein kinase C
71,72
. Another suppressive function of 
insulin by Leptin is by activating phosphodiesterase 3B
73
. This ends up in the suppression 
of cyclic AMP and inhibition of GLP-1 stimulated insulin secretion. Recent advancement 
in studying the action of Leptin in lowering insulin secretion is the consequence of Leptin 
 
 
action on transcription of insulin gene in beta cells of pancreas. Due to this, Preproinsulin 
mRNA levels are reduced to half of its level
74,75
. 
            There exist two hypotheses for the progression of insulin resistance and type 2 
diabetes mellitus in obese persons. In obesity, high Leptin levels are noted. 
Hyperleptinemia causes decrease of insulin secretion caused by hyperglycemia. The next 
hypothesis states that there is a desentisation of Leptin receptors in beta cells of pancreas. 
The consequence of this is defective Leptin receptor signaling and resulting in chronic 
hyperinsulinemia. This paves way for the pathogenesis of diabetes
76
. 
ASSOCIATION OF LEPTIN WITH TYPE 2 DIABETES MELLITUS: 
 
 
         
Source: Seufert J, Kieffer TJ, Leech CA, Holz GG, MoritzW, Ricordi C et al. Leptin 
suppression of insulin secretion and gene expression in human pancreatic islets: 
implications for the development of adipogenic diabetes mellitus. Journal of Clinical 
Endocrinology and Metabolism 1999; 84: 670-676. 
 
 
MATERIALS AND METHODS: 
 
 
The study was conducted at PSG Institute of Medical Sciences and Research, 
Coimbatore. Ethical clearance was obtained from the Institutional Human Ethics 
Committee. An informed consent was taken from the patients before sample collection.  
The study design is case control study in which obese type 2 diabetics (n =40) and 
thin type 2 diabetics (n =40) are selected as cases. The diagnosis of Type 2 diabetes is 
based on case record description which is based on insulin level and other factors at the 
time of diagnosis. Cases were selected from diabetic patients attending Endocrinology 
and Medicine OPD. Patients satisfying the diagnosis, inclusion criteria and BMI 
(measured by the investigator), and not coming under exclusion criteria, were given 
explanation about this study. If they were willing to participate, the consent forms were 
filled and the samples were collected. The samples were processed and stored for 
analysis.  
Control individuals were mainly selected from the master health check up. For 
master health check up patients, weight, height and BMI were available in the case sheet. 
Person fulfilling the control group criteria was requested to participate in the study. If 
they were willing, the consent forms were filled and sample were collected from them. 
Their samples were also processed and stored for analysis. Patient data were retrieved 
from their case sheet.  
 
 
 
 
 
INCLUSION CRITERIA: 
GROUP 1: 
Thin built, diabetic – BMI below 25  
Both males and females 
Age: 30-60 yrs. 
Duration of diabetes - minimum period of 6 months from the date of diagnosis. 
GROUP 2: 
Obese, diabetic – BMI 30 and above  
Males & females 
Age: 30-60 yrs. 
GROUP 3: 
 Thin built, non-diabetic – BMI below 25 
Males & females 
Age: 30-60 yrs. 
 
 
 
 
GROUP 4: 
Obese, non-diabetic - BMI 30 and above 
Age: 30-60yrs. 
Males & Females. 
EXCLUSION CRITERIA: 
Subjects with: 
1. Acute ill patients. 
2. Malignant neoplasm. 
3. End stage renal disease. 
4. Visual/motor/sensory defect. 
5. On treatment for above conditions.  
Collection of blood samples: 
As cases are diabetics and controls are patients attending master health check up, 
fasting sample – fluoride vacutainer for fasting plasma glucose, EDTA vacutainer for 
HbA1c and clot activator vacutainer for lipid profile were collected routinely. The 2
nd
 
hour post prandial plasma glucose sample was also collected routinely. The left over 
serum in the clot activator vacutainer tube used for lipid profile was transferred to 
 
 
secondary labelled plain tube. This sample was stored at -20 degree celcius for Leptin 
assay.  
The methods used for estimation of biochemical parameters were given below. 
 
LEPTIN ELISA: 
 
  To quantify Leptin in serum by an enzyme immunoassay method
77
. 
 
PRINCIPLE OF THE TEST: 
  This is a sandwich type ELISA assay. The assay utilises  two monoclonal antibodies 
which are highly specific. One monoclonal antibody is for Leptin which is immobilized 
in the microtiter plate and the second monoclonal antibody is specific for another epitope 
of Leptin which is biotin conjugated. Initially, sandwich complex is formed by Leptin 
present in the samples and standards  bound to the immobilized antibody and to the 
biotinylated antibody. Then the microtiter plate is washed to remove the excess and 
unbound biotinylated antibody. Following which  streptavidin conjugated horse radish 
peroxidase (HRP) is added. This binds to the bound biotinylated antibody specifically. 
Onceagain microtiter plate is washed to remove the unbound streptavidin – HRP. Then 
enzyme substrate tetramethylbenzidine (TMB) is added. Yellow colour is produced and 
the absorbance is measured at 450nm. 
  
 
 
 
 
 
PROCEDURE: 
Add 20 μl of sample per well. 
 
Add 80 μl of biotinylated antibody per well. Incubate 1 hour. 
 
Wash, then add 100 μl of Streptavidin-HRP conjugate per well. Incubate 30 minutes. 
 
Wash, then add 100 μl of TMB Substrate per well. Incubate 10 minutes. 
 
Add 50 μl of Stop Solution per well. Read at 450 nm immediately. 
 
PLASMA GLUCOSE 
Method: 
Enzymatic reference method with Hexokinase. 
Principle: 
The phosphorylation of glucose by ATP to form glucose-6 phosphate and ADP is 
catalysed by Hexokinase (HK). This is followed by the action of another enzyme, 
glucose-6 phosphate dehydrogenase (G6PDH). This enzyme catalyzes oxidation of 
glucose-6 phosphate by NAD
+
 to form NADH. 
 
 
 
 
Reaction:                           
                                 HK 
D-glucose + ATP                       D-glucose-6 phosphate + ADP 
                                                       G6PDH 
D-glucose-6 phosphate + NAD
+
                       D-6 phosphogluconate +NADH+H
+
  
  
The NADH concentration is directly proportional to the concentration of glucose and the 
increase in absorbance is measured at 340nm. 
 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R-S 
Direction of Reaction Increase 
Wavelength A/B 340/409 nm 
Test value 0-40 mmol/L  
Unit mmol/L 
 
 
 
 
 
 
SERUM TOTAL CHOLESTEROL 
Method: 
Enzymatic colorimetric test. 
The method involves use of enzymes cholesterol esterase, cholesterol oxidase and 
peroxidase. 
Principle: 
Cholesterol esters are cleaved by the action of cholesterol esterase (CE) to yield free 
cholesterol and fatty acids. Cholesterol oxidase (CHOD) in a second reaction helps in the 
formation of cholest-4-en-3-one and hydrogen peroxide by the oxidation of cholesterol. 
Peroxidase (POD) converts the hydrogen peroxide that is formed and helps in the 
oxidative coupling of phenol and 4-aminoantipyrine (AAP) forming a quinone-
imine(red). 
 
Reaction: 
                                                  CE 
Cholesterol esters + H2O                    Cholesterol + R-COOH 
 
                                          CHOD 
Cholesterol + O2                                      Cholest-4-ens-3-one + H2 
                                               POD 
2 H2O2 + 4 AAP + Phenol                   Quinone-imine dye + H2O 
 
 
 
 
The intensity of the red colour produced is directly proportional to the serum cholesterol 
level and is determined by the increase in absorbance measured at 512 nm. 
 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R-S 
Direction of Reaction Increase 
Wavelength A/B 512/659 nm 
Test value 0-20.7 mmol/L 
Unit mmol/L 
 
 
 
SERUM TRIGLYCERIDES: 
Method: 
Enzymatic colorimetric method. 
Involves enzymes glycerol phosphate oxidase and 4-aminophenazone. 
Principle: 
 
 
Lipoprotein lipase (LPL) hydrolyzes the triglycerides to glycerol and fatty acids. Glycerol 
kinase (GK) catalyses the conversion of glycerol to glycerol-3-phosphate with the help of 
ATP phosphorylation. Glycerol phosphate oxidase (GPO) catalyses the oxidation of 
glycerol-3-phosphate to form dihydroxyacetone phosphate and hydrogen peroxide. 
Peroxidase (POD) converts hydrogen peroxide, 4-chlorophenol and 4-aminophenazone to 
form a red-coloured quinoneimine dye. The intensity of color is measured at 512 nm and 
the concentration of triglyceride is assessed in the sample. 
Reaction: 
                             LPL 
Triglycerides                        Glycerol + Fatty acids 
                                GK  
Glycerol + ATP                     Glycerol-3 phosphate + ADP 
                                                    GPO 
Glycerol -3 phosphate + O2                     Dihydroxy acetone Phosphate+H2O2 
                                                      POD 
2 H2O2 + 4 aminophenazone                     Quinoneimine dye+4H2O+4 Chlorophenol 
 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R-S 
 
 
Direction of Reaction Increase 
Wavelength A/B 512/659 nm 
Test range 0-10 mmol/L (0-885 mg/dL) 
Unit mmol/L 
 
SERUM HDL CHOLESTEROL: 
Method: 
Homogenous enzymatic colorimetric assay. 
Principle: 
With magnesium ions, dextran sulphate complexes with LDL, VLDL and chylomicrons 
which are water soluble and resistant to polyethylene glycol (PEG) modified enzymes. 
Cholesterol esterase and cholesterol oxidase associated with PEG to the amino groups is 
used to determine the cholesterol level using enzymatic methods. Cholesterol ester is 
partitioned into free cholesterol and fatty acids with the help of cholesterol esterase. 
Oxidation of cholesterol by cholesterol oxidase is done in the presence of oxygen to Δ4-
cholestenone and hydrogen peroxide. Hydrogen peroxide which is generated reacts with 
4-aminoantipyrine and HSDA in the presence of peroxidase, forms a purple-blue dye. 
The cholesterol concentration is directly proportional to the intensity of blue colour and it 
is measured photometrically. 
 
 
 
 
 
 
Reaction: 
                                        PEG cholesterol esterase 
HDL Cholesterol ester + H2O                     HDL Cholesterol +RCOOH 
                                       PEG Cholesterol oxidase 
HDL-Cholesterol +O2                                     4-cholestenone + H2O2 
                                                                        POD 
2H2O2 + 4 aminoantipyrine + HSDA+H
+ 
                        Purple blue Pigment+4H2O 
 
Test definition:   
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R1-S-SR 
Direction of Reaction Increase 
Wavelength A/B 583/659 nm 
Test range 0-3.12 mmol/L (0-120 mg/dL) 
Unit mmol/L 
 
SERUM LDL CHOLESTEROL: 
Method: 
 
 
Homogeneous enzymatic colorimetric assay. 
 
Principle: 
This method is based on the property of selective micellary solubilization of LDL-
cholesterol by a non-ionic detergent. It also utilizes the interaction of a sugar compound 
with lipoproteins such as VLDL and chylomicrons. Addition of a detergent to the 
enzymes used for cholesterol estimation (cholesterol esterase - cholesterol oxidase 
coupling reaction), increases the relative reactivities of cholesterol in the lipoprotein 
fractions in the following order: HDL < chylomicrons < VLDL < LDL. The activity of 
the enzymes used in the cholesterol estimation is reduced in the presence of magnesium 
ions and a sugar. The selective estimation of LDL-cholesterol in serum is enabled by the 
reaction of a sugar molecule with a detergent. In the presence of oxygen, cholesterol is 
oxidized by cholesterol oxidase to Δ4-cholestenone and hydrogen peroxide. The intensity 
of the blue quinoneimine dye formed is directly proportional to the concentration of LDL 
cholesterol. It is determined by monitoring the increase in absorbance at 583 nm. 
Reaction: 
                              Detergent cholesterol esterase 
LDL-Cholesterol ester + H2O                 Cholesterol + Free fatty acid 
 
                             Cholesterol oxidase 
LDL-Cholesterol + O2                       Δ4-cholestenone + H2O2 
 
 
 
2H2O2 + 4 aminoantipyrine + HSDA+H
+
                 Purple blue pigment+4H2O 
 
Test definition: 
 
 
 
Glycated haemoglobin: (HbA1c) 
Method: 
Turbidimetric inhibition immunoassay 
Principle: 
EDTA tube collected whole blood specimen is hemolysed after collection. Total 
hemoglobin and HbA1c concentrations are determined. Total hemoglobin is measured 
colorimetrically. The percentage of HbA1c is determined immunoturbidimetrically. The 
ratio of both these levels gives the final percent HbA1c result. 
                     EDTA collected blood is hemolysed with hemolysis reagent in the 
predilution cuvette. This leads to reduction in osmotic pressure which lyses the 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R1-S-SR 
Direction of Reaction Increase 
Wavelength A/B 583/659 nm 
Test range 0-14.2 mmol/L ( 0-550 mg/dL) 
Unit mmol/L 
 
 
erythrocytes. Lysis of erythrocytes releases the haemoglobin. It is degraded by the 
proteolytic action of the enzyme pepsin. This renders the beta-N terminal structures more 
available for the immunoassay. In the hemolysate, a colorimetric method helps in the 
determination of total haemoglobin. This is done on the basis of production of a 
brownish-green chromophore. This occurs in alkaline detergent solution using a cyanide 
free method. The intensity of color relates to the level of total hemoglobin in the sample. 
The concentration is calculated by sensing the raise in the absorbance at 552nm. A fixed 
factor that is obtained from the primary calibrator chlorohemin calculates the test results.  
                   Turbidimetric method to measure HbA1c is done using monoclonal 
antibodies which are present attached to latex particles. The monoclonal antibodies bind 
the amino terminal fragments of HbA1c. The unbound free antibodies agglutinate with an 
artificial polymer. The change in turbidity is inversely related to the quantity of bound 
glycated proteins. This is measured turbidimetrically at 552nm. HbA1c result is given as 
percentage of HbA1c. It is evaluated from the ratio of HbA1c/Hb as given below:  
 
According to IFCC 
HbA1c (%) = ( HbA1c / Hb) x 100 
According to DCCT/NGSP 
HbA1c(%) = (HbA1c/Hb) x 87.6 + 2.27 
 
 
 
 
 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction D-R1-S-SR 
Direction of Reaction Increase 
Wavelength A/B 552nm 
Test range 1.4-4.7μmol/L (2.4-75.8mg/dL) 
Unit μmol/L 
 
 
 
 
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS: 
 The data obtained after the estimation of Leptin, Body Mass Index, Fasting 
Glucose, Post Prandial Glucose, Cholesterol, Triglycerides, HDL, LDL and HbA1c were 
statistically analyzed using IBM SPSS software version 19. 
 The data distribution was displayed by histogram, dot plot and scatter plot. The 
data summary was represented by bar diagram.  
The dependence of categorical variable was tested with Chi Square test. For 
comparing two groups t test was used. For comparing multiple group means one way 
ANOVA (Analysis Of Variance) was done. For post hoc testing, Tukey and Games 
Howel were used according to the group n and equivalence of variance. Significance was 
assessed at 5% level. 
 The correlation between quantitative parameters were done using Pearson and 
further checked with scatter plot. For correction of right side skewed data, natural 
logarithm transformation was used.  
 
  
 
 
 
 
 
RESULTS:  
The age, sex and BMI distribution of the study groups are given in the figures 1, 2 
& 3 respectively. This shows the even matching of cases and controls. But the BMI of 
obese subjects in both cases and controls were more clustered around 30.  The glucose 
values in fasting and postprandial states of the cases and controls are given in the bar 
diagram (figure 4) is consistent with diabetic and non diabetic groups. 
The distribution of values of various parameters in the four groups is given in 
figures 5 to 11. Fasting glucose, Post prandial glucose and HbA1c are low in control 
group as expected. The distribution of Cholesterol, HDL cholesterol and LDL cholesterol 
are similar in all groups. The triglycerides distribution is towards lower side in Thin-non-
diabetic group. 
Leptin distribution was confined to lower side both in thin diabetic and thin non 
diabetic groups while there is some dispersion to higher side in obese groups. The Leptin 
distribution in obese diabetic group shows a right skewing. So the natural logarithm and 
log10 transformations were applied to the distribution. After the transformation the 
distribution was showing slight right skewing in all groups except the obese diabetic 
group. Anyhow the natural logarithm of Leptin was used for examining the correlation 
between quantitative variables. The correlation coefficients are presented in Table 14 and 
the corresponding scatter plots are given in the figure 16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1: COMPARISON OF AGE AMONG STUDY GROUPS 
 
ANOVA 
Age 
 Sum of Squares df Mean Square F Sig. 
Between Groups 627.769 3 209.256 3.428 .019 
Within Groups 9522.725 156 61.043   
Total 10150.494 159    
 
 
 
 
 
 
Multiple Comparisons 
Age 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic .225 1.747 .999 -4.31 4.76 
Thin Nondiabetic 3.600 1.747 .171 -.94 8.14 
Obese Nondiabetic 4.450 1.747 .057 -.09 8.99 
Obese Diabetic Thin Diabetic -.225 1.747 .999 -4.76 4.31 
Thin Nondiabetic 3.375 1.747 .219 -1.16 7.91 
Obese Nondiabetic 4.225 1.747 .078 -.31 8.76 
Thin Nondiabetic Thin Diabetic -3.600 1.747 .171 -8.14 .94 
Obese Diabetic -3.375 1.747 .219 -7.91 1.16 
Obese Nondiabetic .850 1.747 .962 -3.69 5.39 
Obese Nondiabetic Thin Diabetic -4.450 1.747 .057 -8.99 .09 
Obese Diabetic -4.225 1.747 .078 -8.76 .31 
Thin Nondiabetic -.850 1.747 .962 -5.39 3.69 
 
 
 
 
 
 
According to CHI-SQUARE test, p value was found to be 0.266 (Not Significant) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2: COMPARISON OF BMI AMONG STUDY GROUPS 
 
ANOVA 
BMI 
 Sum of Squares df Mean Square F Sig. 
Between Groups 5747.804 3 1915.935 243.922 .000 
Within Groups 1225.336 156 7.855   
Total 6973.139 159    
 
 
 
 
 
Multiple Comparisons 
BMI 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic -11.7255
*
 .6267 .000 -13.353 -10.098 
Thin Nondiabetic 1.7827
*
 .6267 .026 .155 3.410 
Obese Nondiabetic -10.2408
*
 .6267 .000 -11.868 -8.613 
Obese Diabetic Thin Diabetic 11.7255
*
 .6267 .000 10.098 13.353 
Thin Nondiabetic 13.5083
*
 .6267 .000 11.881 15.136 
Obese Nondiabetic 1.4848 .6267 .087 -.143 3.112 
Thin Nondiabetic Thin Diabetic -1.7827
*
 .6267 .026 -3.410 -.155 
Obese Diabetic -13.5083
*
 .6267 .000 -15.136 -11.881 
Obese Nondiabetic -12.0235
*
 .6267 .000 -13.651 -10.396 
Obese Nondiabetic Thin Diabetic 10.2408
*
 .6267 .000 8.613 11.868 
Obese Diabetic -1.4848 .6267 .087 -3.112 .143 
Thin Nondiabetic 12.0235
*
 .6267 .000 10.396 13.651 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
FIGURE 4: FASTING AND POST PRANDIAL GLUCOSE LEVELS IN 
STUDY GROUPS 
 
 
 
 
 
  
 
 
 
 
 
 
1 -  THIN DIABETIC 
2 -  OBESE DIABETIC 
3 -  THIN NON- DIABETIC 
4 -  OBESE NON - DIABETIC 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3: COMPARISON OF FASTING GLUCOSE LEVEL AMONG STUDY 
GROUPS 
 
ANOVA 
Fasting glucose mg/dL 
 Sum of Squares df Mean Square F Sig. 
Between Groups 180580.069 3 60193.356 24.205 .000 
Within Groups 387944.925 156 2486.826   
Total 568524.994 159    
 
 
 
 
 
 
 
 
Multiple Comparisons 
Fasting glucose mg/dL 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic 33.825
*
 11.151 .015 4.87 62.78 
Thin Nondiabetic 82.850
*
 11.151 .000 53.89 111.81 
Obese Nondiabetic 76.200
*
 11.151 .000 47.24 105.16 
Obese Diabetic Thin Diabetic -33.825
*
 11.151 .015 -62.78 -4.87 
Thin Nondiabetic 49.025
*
 11.151 .000 20.07 77.98 
Obese Nondiabetic 42.375
*
 11.151 .001 13.42 71.33 
Thin Nondiabetic Thin Diabetic -82.850
*
 11.151 .000 -111.81 -53.89 
Obese Diabetic -49.025
*
 11.151 .000 -77.98 -20.07 
Obese Nondiabetic -6.650 11.151 .933 -35.61 22.31 
Obese Nondiabetic Thin Diabetic -76.200
*
 11.151 .000 -105.16 -47.24 
Obese Diabetic -42.375
*
 11.151 .001 -71.33 -13.42 
Thin Nondiabetic 6.650 11.151 .933 -22.31 35.61 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
 
 
 
 
1 -  THIN DIABETIC 
2 -  OBESE DIABETIC 
3 -  THIN NON- DIABETIC 
4 -  OBESE NON - DIABETIC 
 
 
 
 
 
 
 
 
 
TABLE 4: COMPARISON OF POST PRANDIAL GLUCOSE LEVEL AMONG STUDY 
GROUPS 
 
ANOVA 
Pp glucose mg/dL 
 Sum of Squares df Mean Square F Sig. 
Between Groups 627509.469 3 209169.823 30.332 .000 
Within Groups 1075775.625 156 6895.998   
Total 1703285.094 159    
 
 
 
 
 
 
 
Multiple Comparisons 
Pp glucose mg/dL 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic 38.800 18.569 .161 -9.42 87.02 
Thin Nondiabetic 149.225
*
 18.569 .000 101.00 197.45 
Obese Nondiabetic 132.900
*
 18.569 .000 84.68 181.12 
Obese Diabetic Thin Diabetic -38.800 18.569 .161 -87.02 9.42 
Thin Nondiabetic 110.425
*
 18.569 .000 62.20 158.65 
Obese Nondiabetic 94.100
*
 18.569 .000 45.88 142.32 
Thin Nondiabetic Thin Diabetic -149.225
*
 18.569 .000 -197.45 -101.00 
Obese Diabetic -110.425
*
 18.569 .000 -158.65 -62.20 
Obese Nondiabetic -16.325 18.569 .816 -64.55 31.90 
Obese Nondiabetic Thin Diabetic -132.900
*
 18.569 .000 -181.12 -84.68 
Obese Diabetic -94.100
*
 18.569 .000 -142.32 -45.88 
Thin Nondiabetic 16.325 18.569 .816 -31.90 64.55 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
 
 
 
 
1 -  THIN DIABETIC 
2 -  OBESE DIABETIC 
3 -  THIN NON- DIABETIC 
4 -  OBESE NON - DIABETIC 
 
 
 
 
 
TABLE 5: COMPARISON OF HbA1c LEVEL AMONG STUDY GROUPS 
 
ANOVA 
A1c % 
 Sum of Squares df Mean Square F Sig. 
Between Groups 255.236 3 85.079 45.020 .000 
Within Groups 294.805 156 1.890   
Total 550.041 159    
 
 
 
 
Multiple Comparisons 
A1c % 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic .54100 .30739 .297 -.2573 1.3393 
Thin Nondiabetic 2.89175
*
 .30739 .000 2.0935 3.6900 
Obese Nondiabetic 2.62925
*
 .30739 .000 1.8310 3.4275 
Obese Diabetic Thin Diabetic -.54100 .30739 .297 -1.3393 .2573 
Thin Nondiabetic 2.35075
*
 .30739 .000 1.5525 3.1490 
Obese Nondiabetic 2.08825
*
 .30739 .000 1.2900 2.8865 
Thin Nondiabetic Thin Diabetic -2.89175
*
 .30739 .000 -3.6900 -2.0935 
Obese Diabetic -2.35075
*
 .30739 .000 -3.1490 -1.5525 
Obese Nondiabetic -.26250 .30739 .828 -1.0608 .5358 
Obese Nondiabetic Thin Diabetic -2.62925
*
 .30739 .000 -3.4275 -1.8310 
Obese Diabetic -2.08825
*
 .30739 .000 -2.8865 -1.2900 
Thin Nondiabetic .26250 .30739 .828 -.5358 1.0608 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
 
TABLE 6: COMPARISON OF CHOLESTEROL LEVEL AMONG STUDY GROUPS 
 
ANOVA 
Cholesterol mg/dL 
 Sum of Squares df Mean Square F Sig. 
Between Groups 12432.850 3 4144.283 2.473 .064 
Within Groups 261462.250 156 1676.040   
Total 273895.100 159    
 
 
 
 
 
 
 
1 -  THIN DIABETIC 
2 -  OBESE DIABETIC 
3 -  THIN NON- DIABETIC 
4 -  OBESE NON - DIABETIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 7: COMPARISON OF TRIGLYCERIDE LEVEL  AMONG STUDY GROUPS 
 
ANOVA 
Triglycerides mg/dL 
 Sum of Squares df Mean Square F Sig. 
Between Groups 87716.869 3 29238.956 5.997 .001 
Within Groups 760623.875 156 4875.794   
Total 848340.744 159    
 
 
 
 
 
 
Multiple Comparisons 
Triglycerides mg/dL 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic 20.625 15.614 .551 -19.92 61.17 
Thin Nondiabetic 64.650
*
 15.614 .000 24.10 105.20 
Obese Nondiabetic 24.450 15.614 .401 -16.10 65.00 
Obese Diabetic Thin Diabetic -20.625 15.614 .551 -61.17 19.92 
Thin Nondiabetic 44.025
*
 15.614 .028 3.48 84.57 
Obese Nondiabetic 3.825 15.614 .995 -36.72 44.37 
Thin Nondiabetic Thin Diabetic -64.650
*
 15.614 .000 -105.20 -24.10 
Obese Diabetic -44.025
*
 15.614 .028 -84.57 -3.48 
Obese Nondiabetic -40.200 15.614 .053 -80.75 .35 
Obese Nondiabetic Thin Diabetic -24.450 15.614 .401 -65.00 16.10 
Obese Diabetic -3.825 15.614 .995 -44.37 36.72 
Thin Nondiabetic 40.200 15.614 .053 -.35 80.75 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
 
TABLE 8: COMPARISON OF HDL LEVEL AMONG STUDY GROUPS 
 
ANOVA 
Hdl mg/dL 
 Sum of Squares df Mean Square F Sig. 
Between Groups 337.769 3 112.590 .605 .613 
Within Groups 29054.425 156 186.246   
Total 29392.194 159    
 
 
 
 
 
 
 
 
1 -  THIN DIABETIC 
2 -  OBESE DIABETIC 
3 -  THIN NON- DIABETIC 
4 -  OBESE NON - DIABETIC 
 
 
 
 
 
 
 
 
TABLE 9: COMPARISON OF LDL LEVEL AMONG STUDY GROUPS 
 
ANOVA 
Ldl mg/dL 
 Sum of Squares df Mean Square F Sig. 
Between Groups 11310.950 3 3770.317 3.039 .031 
Within Groups 193508.950 156 1240.442   
Total 204819.900 159    
 
 
 
 
Multiple Comparisons 
Ldl mg/dL 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic -8.175 7.875 .727 -28.63 12.28 
Thin Nondiabetic -4.250 7.875 .949 -24.70 16.20 
Obese Nondiabetic -22.375
*
 7.875 .026 -42.83 -1.92 
Obese Diabetic Thin Diabetic 8.175 7.875 .727 -12.28 28.63 
Thin Nondiabetic 3.925 7.875 .959 -16.53 24.38 
Obese Nondiabetic -14.200 7.875 .276 -34.65 6.25 
Thin Nondiabetic Thin Diabetic 4.250 7.875 .949 -16.20 24.70 
Obese Diabetic -3.925 7.875 .959 -24.38 16.53 
Obese Nondiabetic -18.125 7.875 .102 -38.58 2.33 
Obese Nondiabetic Thin Diabetic 22.375
*
 7.875 .026 1.92 42.83 
Obese Diabetic 14.200 7.875 .276 -6.25 34.65 
Thin Nondiabetic 18.125 7.875 .102 -2.33 38.58 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
 
 
 
1 -  THIN DIABETIC 
2 -  OBESE DIABETIC 
3 -  THIN NON- DIABETIC 
4 -  OBESE NON - DIABETIC 
 
 
 
 
 
 
 
 
 
TABLE 10: COMPARISON OF LEPTIN LEVEL AMONG STUDY GROUPS 
 
ANOVA 
Leptin value 
 Sum of Squares df Mean Square F Sig. 
Between Groups 68598.467 3 22866.156 23.591 .000 
Within Groups 151205.469 156 969.266   
Total 219803.936 159    
 
 
 
 
Multiple Comparisons 
Leptin value 
Tukey HSD 
(I) Study groups (J) Study groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Thin Diabetic Obese Diabetic -43.97500
*
 6.96156 .000 -62.0537 -25.8963 
Thin Nondiabetic .28750 6.96156 1.000 -17.7912 18.3662 
Obese Nondiabetic -38.15000
*
 6.96156 .000 -56.2287 -20.0713 
Obese Diabetic Thin Diabetic 43.97500
*
 6.96156 .000 25.8963 62.0537 
Thin Nondiabetic 44.26250
*
 6.96156 .000 26.1838 62.3412 
Obese Nondiabetic 5.82500 6.96156 .837 -12.2537 23.9037 
Thin Nondiabetic Thin Diabetic -.28750 6.96156 1.000 -18.3662 17.7912 
Obese Diabetic -44.26250
*
 6.96156 .000 -62.3412 -26.1838 
Obese Nondiabetic -38.43750
*
 6.96156 .000 -56.5162 -20.3588 
Obese Nondiabetic Thin Diabetic 38.15000
*
 6.96156 .000 20.0713 56.2287 
Obese Diabetic -5.82500 6.96156 .837 -23.9037 12.2537 
Thin Nondiabetic 38.43750
*
 6.96156 .000 20.3588 56.5162 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
FIGURE 13: LEPTIN LEVEL IN STUDY SUB GROUPS 
 
 
 
 
 
TABLE 11: COMPARISON OF LEPTIN LEVEL AMONG STUDY SUB GROUPS 
 
ANOVA 
Leptin value 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 98556.354 7 14079.479 17.651 .000 
Within Groups 121247.582 152 797.681   
Total 219803.936 159    
 
 
 
TABLE 12: COMPARISON OF LEPTIN LEVEL AMONG STUDY SUB GROUPS 
BASED ON GENDER 
 
 
 
Multiple Comparisons - Leptin value 
Games-Howell 
(I) EightGps (J) EightGps 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Thin Diabetic 
Female 
ThinDiabeticMale 9.19780 3.17764 .117 -1.3043 19.6999 
ObeseDiabeticFemale -63.12406
*
 15.15967 .010 -114.4808 -11.7674 
ObeseDiabeticMale -15.26190 7.14256 .419 -38.7673 8.2435 
ThinNonDiabeticFemale -1.43985 4.13210 1.000 -14.8541 11.9744 
ThinNonDiabeticMale 13.23810
*
 3.06527 .006 2.9945 23.4817 
ObeseNonDiabeticFemale -41.90476
*
 4.96636 .000 -58.0128 -25.7967 
ObeseNonDiabeticMale -21.41353
*
 6.34706 .043 -42.3715 -.4556 
Thin Diabetic 
Male 
ThinDiabeticFemale -9.19780 3.17764 .117 -19.6999 1.3043 
ObeseDiabeticFemale -72.32186
*
 15.03079 .003 -123.4321 -21.2116 
ObeseDiabeticMale -24.45971
*
 6.86478 .030 -47.2990 -1.6204 
ThinNonDiabeticFemale -10.63765 3.63090 .103 -22.4858 1.2105 
ThinNonDiabeticMale 4.04029 2.34628 .673 -3.4155 11.4961 
ObeseNonDiabeticFemale -51.10256
*
 4.55784 .000 -66.0508 -36.1544 
ObeseNonDiabeticMale -30.61134
*
 6.03277 .001 -50.8098 -10.4128 
Obese Diabetic 
Female 
ThinDiabeticFemale 63.12406
*
 15.15967 .010 11.7674 114.480
8 
ThinDiabeticMale 72.32186
*
 15.03079 .003 21.2116 123.432
1 
ObeseDiabeticMale 47.86216 16.33534 .109 -6.0588 101.783
1 
ThinNonDiabeticFemale 61.68421
*
 15.26112 .012 10.1314 113.237
0 
ThinNonDiabeticMale 76.36216
*
 15.00744 .001 25.2948 127.429
5 
ObeseNonDiabeticFemale 21.21930 15.50781 .861 -30.8341 73.2727 
ObeseNonDiabeticMale 41.71053 16.00352 .203 -11.4412 94.8623 
 
 
Obese Diabetic 
Male 
ThinDiabeticFemale 15.26190 7.14256 .419 -8.2435 38.7673 
ThinDiabeticMale 24.45971
*
 6.86478 .030 1.6204 47.2990 
ObeseDiabeticFemale -47.86216 16.33534 .109 -101.7831 6.0588 
ThinNonDiabeticFemale 13.82206 7.35542 .575 -10.1969 37.8410 
ThinNonDiabeticMale 28.50000
*
 6.81350 .008 5.7691 51.2309 
ObeseNonDiabeticFemale -26.64286
*
 7.85447 .034 -51.9945 -1.2912 
ObeseNonDiabeticMale -6.15163 8.79278 .997 -34.3483 22.0451 
Thin NonDiabetic 
Female 
ThinDiabeticFemale 1.43985 4.13210 1.000 -11.9744 14.8541 
ThinDiabeticMale 10.63765 3.63090 .103 -1.2105 22.4858 
ObeseDiabeticFemale -61.68421
*
 15.26112 .012 -113.2370 -10.1314 
ObeseDiabeticMale -13.82206 7.35542 .575 -37.8410 10.1969 
ThinNonDiabeticMale 14.67794
*
 3.53298 .006 3.0659 26.2900 
ObeseNonDiabeticFemale -40.46491
*
 5.26790 .000 -57.3973 -23.5325 
ObeseNonDiabeticMale -19.97368 6.58568 .084 -41.5112 1.5638 
Thin NonDiabetic 
Male 
ThinDiabeticFemale -13.23810
*
 3.06527 .006 -23.4817 -2.9945 
ThinDiabeticMale -4.04029 2.34628 .673 -11.4961 3.4155 
ObeseDiabeticFemale -76.36216
*
 15.00744 .001 -127.4295 -25.2948 
ObeseDiabeticMale -28.50000
*
 6.81350 .008 -51.2309 -5.7691 
ThinNonDiabeticFemale -14.67794
*
 3.53298 .006 -26.2900 -3.0659 
ObeseNonDiabeticFemale -55.14286
*
 4.48022 .000 -69.9116 -40.3741 
ObeseNonDiabeticMale -34.65163
*
 5.97434 .000 -54.7305 -14.5728 
Obese 
NonDiabetic 
Female 
ThinDiabeticFemale 41.90476
*
 4.96636 .000 25.7967 58.0128 
ThinDiabeticMale 51.10256
*
 4.55784 .000 36.1544 66.0508 
ObeseDiabeticFemale -21.21930 15.50781 .861 -73.2727 30.8341 
ObeseDiabeticMale 26.64286
*
 7.85447 .034 1.2912 51.9945 
ThinNonDiabeticFemale 40.46491
*
 5.26790 .000 23.5325 57.3973 
ThinNonDiabeticMale 55.14286
*
 4.48022 .000 40.3741 69.9116 
ObeseNonDiabeticMale 20.49123 7.13874 .111 -2.5581 43.5406 
Obese 
NonDiabetic Male 
ThinDiabeticFemale 21.41353
*
 6.34706 .043 .4556 42.3715 
ThinDiabeticMale 30.61134
*
 6.03277 .001 10.4128 50.8098 
ObeseDiabeticFemale -41.71053 16.00352 .203 -94.8623 11.4412 
ObeseDiabeticMale 6.15163 8.79278 .997 -22.0451 34.3483 
ThinNonDiabeticFemale 19.97368 6.58568 .084 -1.5638 41.5112 
ThinNonDiabeticMale 34.65163
*
 5.97434 .000 14.5728 54.7305 
ObeseNonDiabeticFemale -20.49123 7.13874 .111 -43.5406 2.5581 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 13: LEPTIN LEVEL IN MALE & FEMALE SUBJECTS 
 
Group Statistics 
 VAR00001 N Mean Std. Deviation Std. Error Mean 
Leptin value Male 87 22.3448 24.56036 2.63315 
Female 73 48.7877 44.12309 5.16422 
 
 
  
Independent Samples Test 
 
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Leptin 
value 
Equal variances 
assumed 
12.07 .001 -4.78 158 .000 -26.44 5.53 -37.37 -15.51 
Equal variances 
not assumed 
  
-4.56 108.18 .000 -26.44 5.79 -37.93 -14.95 
 
          
 
 
 
 
 
 
 
 
 
    FIGURE 15: SCATTER PLOTS OF LEPTIN WITH VARIOUS PARAMETERS 
 
 
 
          
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 14: CORRELATION OF VARIOUS BIOCHEMICAL PARAMETERS AMONG  
 
STUDY POPULATION. 
 
 
 
 
Age BMI Glufas Glupp Chol Tgl Hdl Ldl A1c Leptin LeptinLn 
Age 1.00 0.01 0.06 0.08 
-
0.03 
-
0.03 
-
0.02 
-
0.03 0.22 0.06 0.00 
BMI 0.01 1.00 -0.08 -0.03 0.13 0.09 
-
0.08 0.15 0.02 0.60 0.70 
Glufas 0.06 
-
0.08 1.00 0.84 0.14 0.39 
-
0.08 0.09 0.72 -0.08 -0.11 
Glupp 0.08 
-
0.03 0.84 1.00 0.06 0.30 
-
0.06 0.02 0.72 -0.08 -0.04 
Chol 
-
0.03 0.13 0.14 0.06 1.00 0.51 0.07 0.92 0.01 0.13 0.16 
Tgl 
-
0.03 0.09 0.39 0.30 0.51 1.00 
-
0.26 0.44 0.26 0.05 0.03 
Hdl 
-
0.02 
-
0.08 -0.08 -0.06 0.07 
-
0.26 1.00 
-
0.21 
-
0.10 0.00 0.06 
Ldl 
-
0.03 0.15 0.09 0.02 0.92 0.44 
-
0.21 1.00 
-
0.03 0.12 0.12 
A1c 0.22 0.02 0.72 0.72 0.01 0.26 
-
0.10 
-
0.03 1.00 0.00 -0.01 
Leptin 0.06 0.60 -0.08 -0.08 0.13 0.05 0.00 0.12 0.00 1.00 0.79 
LeptinLn 0.00 0.70 -0.11 -0.04 0.16 0.03 0.06 0.12 
-
0.01 0.79 1.00 
 
 
 
 
 
 
 
 
 
 
 
          FIGURE 16: SCATTER PLOTS OF SIGNIFICANT CORRELATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION: 
 The age distribution of the 4 study groups were between 30 and 60 years. But in 
the diabetic groups and thin non-diabetic group the distribution was more towards 60 
years. In the obese non diabetic group the distribution was uniform throughout the age 
range. Though this difference was slightly reflected in ANOVA with a significance of 
0.019, the post hoc Tukey test didn‟t show difference between these groups. 
 The sex distribution was even and there was no significant difference in Chi 
Square test. The distribution of BMI was according to the inclusion criteria used to 
separate the groups. 
The fasting and corresponding post prandial plasma glucose levels were shown in 
the figures 4 & 5. As expected the non diabetic groups were having lower values while 
the diabetic groups were having higher values. Interestingly, the thin diabetic group was 
having higher plasma glucose level than the obese diabetic. The distribution of fasting 
plasma glucose values, shown as dot plot of different groups, also illustrates the same. In 
the between group ANOVA, the thin diabetic group have a significant higher mean than 
the obese diabetic. But this was not observed in post prandial plasma glucose levels. 
Otherwise, the anticipated significant differences between diabetic and non diabetic 
groups were observed in dot plots and ANOVA.  
 
 
HbA1c data was clearly divided between diabetic and non diabetic groups. There 
was no difference between obese and thin. This was in accordance with a study 
performed by Ghorban Mohammadzadeh et al
77
. 
Among the lipid profile parameters, total cholesterol and HDL cholesterol showed 
no significant differences between the four groups. LDL cholesterol of obese non diabetic 
was significantly higher than the thin diabetic. Triglyceride levels were significantly 
lower in thin non diabetic group than other groups.  
  Leptin distribution was also clearly divided between obese and thin, irrespective 
of diabetic status and this result was consistent with the studies conducted by Piyali Das 
et al
78
. We examined the influence of sex. The female group mean was significantly 
different from male group mean. This mandates sex wise sub grouping and comparison. 
The sub group wise Leptin level distribution was given in the Table 12. The comparison 
of the sub group was done by ANOVA and Games Howel post hoc test as the numbers of 
data in each group were not equal and the equivalence of the variance cannot be assumed. 
 The eight sub groups were compared with each other and 56 combinations were 
possible. Significant difference in Leptin level was observed between obese and thin in 
26 combinations (coloured yellow).  Obesity was associated with higher level of Leptin. 
In 19 combinations (green) there was no difference and here the uniting factor among the 
comparisons was obese versus obese or thin versus thin. Hence, in 45 out of 56 
combinations the deciding factor was obese/thin.  
 
 
 Among the remaining groups, 6 combinations (orange) have no significant 
difference between the groups. Here the obesity/thin and male/female effects were acting 
in opposite direction, resulting in no significant difference. There was a significant 
difference in 5 combinations (blue) and here the deciding factor was sex. Females have 
higher Leptin level. Our result was consistent with the finding of Couillard et al and 
many other studies which showed that Leptin level increases in females
79
. This was due 
to the fact that women have higher percentage of fat in the body. Females have increased 
ratio of subcutaneous to visceral fat. This was consistent with the finding that Leptin 
strongly correlates with the body fat mass. Few studies illustrate that there was an 
unconstrained production of Leptin by adipocytes in women than men
80
.  Casabiel et al 
have demonstrated that females have higher percentage of subcutaneous to omental 
Leptin mRNA expression
81
. Estrogens stimulate Leptin secretion in women and 
androgens have an inhibitory effect
80
. 
The correlation between the quantitative parameters was assessed by correlation 
coefficient and scatter plots. BMI–Leptin correlation had an r value of 0.6 and the scatter 
plot also showed a linear positive correlation. Log transformed Leptin levels showed 
even better correlation with r value 0.7. Ahsan et al have showed the same finding
82
. 
  
 
 
 
 
Positive correlation was also observed between following parameters:  
Fasting glucose and post prandial glucose, 
 Fasting glucose and HbA1c,  
Post prandial glucose and HbA1c &  
Total cholesterol and LDL cholesterol . 
These correlations were well established relations. There were negative 
correlations in Triglyceride-HDL cholesterol and HDL cholesterol-LDL cholesterol pairs, 
which were not supported in their respective scatter plot. These negative correlations 
were also expected ones only.  
  
 
 
 
 
 
 
 
 
 
Conclusion: 
1. Leptin is not elevated in thin diabetic when compared with thin non-diabetic. The 
development of type 2 diabetes mellitus in thin individuals may not be related to 
Leptin level. 
2. Obesity and Female sex are associated with increased Leptin level and not with 
type 2 diabetes mellitus. 
3. BMI and Leptin have a linear positive correlation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary: 
The possibility of evolving Diabetes Mellitus rises with the upper limit of body 
mass index. Genetic, lifestyle and environmental factors combined together promotes 
obesity. Diabetes mellitus is a multifactorial disorder characterized by chronic 
hyperglycemia. It is associated with alterations in carbohydrate, protein and fat 
metabolism due to defective insulin secretion or action or both
.
 
Leptin the product of ob gene is a protein hormone secreted by adipocytes and also 
by placenta, bone marrow, muscle, etc. It has a major role in maintaining body weight 
and in energy metabolism. The hypothalamus is the predominant site of action of Leptin. 
Receptors for Leptin is present in various sites like brain and peripheral tissues like 
pancreas, liver, lungs, adipose tissues, T-lymphocytes and epithelial cells. This gives the 
evidence for the role of Leptin in carbohydrate metabolism, reproduction and many other 
functions. Leptin exhibits its insulin lowering action through the receptors present in beta 
cells of pancreas. 
This study was an attempt to know about the Leptin levels in four groups namely 
thin diabetic, obese diabetic, thin non-diabetic and obese non-diabetic populations. Other 
parameters like Fasting and Post Prandial Glucose, HbA1c, Cholesterol, Triglycerides, 
High Density Lipoprotein and Low Density Lipoprotein were also considered. 
In each group 40 subjects were recruited. Their samples were collected and Leptin 
was assayed using Leptin ELISA kit. Fasting and Post Prandial Glucose, HbA1c, 
 
 
Cholesterol, Triglycerides, High Density Lipoprotein and Low Density Lipoprotein were 
analyzed in autoanalyzer. There was no significant difference in Leptin levels in both 
obese diabetic and obese control groups. Leptin level was confined to the lower side in 
thin groups. There was a significant positive correlation between Leptin and body mass 
index. Female subjects have got increased Leptin value than male subjects. This confers 
that Leptin is a marker of obesity rather than Diabetes Mellitus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FUTURE SCOPE OF THE STUDY: 
As Leptin has no association with Type 2 Diabetes Mellitus, other adipocytokines  
( Ghrelin, Resistin, Serpin, Adiponectin, Intelectin, etc) can be looked for the 
Pathogenesis of  Type 2 Diabetes Mellitus in thin individuals. 
Metabolomics study comparing thin and obese type 2 diabetic may be carried out. 
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ANNEXURE: 
DATA COLLECTION TOOL (QUESTIONNAIRE) 
1. Age: 
2. Sex: 
3. Height: 
4. Weight: 
5. BMI: 
6. History of illness: 
           6.1. Diabetes:   Type 1         Type 2 
           6.2. Duration of diabetes:  
           6.3. Hypertension:    1. Yes      2. No 
           6.4. Smoking history: 
           6.5. History of myocardial infarction / Angina / LV dysfunction:                            
                                               1. Yes     2. No 
           6.7. Motor/sensory functions:     
6.8. Duration of treatment: 
 7.  Lab investigations:     
 
 
 
